Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Modification of the TNM Staging System for Stage II/III Gastric Cancer Based on a Prognostic Single Patient Classifier Algorithm

  • Choi, Yoon Young (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Jang, Eunji (MediBio-Informatics Research Center, Novomics Co., Ltd.) ;
  • Seo, Won Jun (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Son, Taeil (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Kim, Hyoung-Il (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Kim, Hyeseon (MediBio-Informatics Research Center, Novomics Co., Ltd.) ;
  • Hyung, Woo Jin (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Huh, Yong-Min (Yonsei Biomedical Research Institute, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Noh, Sung Hoon (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine) ;
  • Cheong, Jae-Ho (Department of Surgery, Yonsei University Health System, Yonsei University College of Medicine)
  • Received : 2018.04.15
  • Accepted : 2018.05.15
  • Published : 2018.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The modification of the cancer classification system aimed to improve the classical anatomy-based tumor, node, metastasis (TNM) staging by considering tumor biology, which is associated with patient prognosis, because such information provides additional precision and flexibility. Materials and Methods: We previously developed an mRNA expression-based single patient classifier (SPC) algorithm that could predict the prognosis of patients with stage II/III gastric cancer. We also validated its utilization in clinical settings. The prognostic single patient classifier (pSPC) differentiates based on 3 prognostic groups (low-, intermediate-, and high-risk), and these groups were considered as independent prognostic factors along with TNM stages. We evaluated whether the modified TNM staging system based on the pSPC has a better prognostic performance than the TNM 8th edition staging system. The data of 652 patients who underwent gastrectomy with curative intent for gastric cancer between 2000 and 2004 were evaluated. Furthermore, 2 other cohorts (n=307 and 625) from a previous study were assessed. Thus, 1,584 patients were included in the analysis. To modify the TNM staging system, one-grade down-staging was applied to low-risk patients according to the pSPC in the TNM 8th edition staging system; for intermediate- and high-risk groups, the modified TNM and TNM 8th edition staging systems were identical. Results: Among the 1,584 patients, 187 (11.8%), 664 (41.9%), and 733 (46.3%) were classified into the low-, intermediate-, and high-risk groups, respectively, according to the pSPC. pSPC prognoses and survival curves of the overall population were well stratified, and the TNM stage-adjusted hazard ratios of the intermediate- and high-risk groups were 1.96 (95% confidence interval [CI], 1.41-2.72; P<0.001) and 2.54 (95% CI, 1.84-3.50; P<0.001), respectively. Using Harrell's C-index, the prognostic performance of the modified TNM system was evaluated, and the results showed that its prognostic performance was better than that of the TNM 8th edition staging system in terms of overall survival (0.635 vs. 0.620, P<0.001). Conclusions: The pSPC-modified TNM staging is an alternative staging system for stage II/III gastric cancer.

Keywords

Acknowledgement

Supported by : Yonsei University College of Medicine

References

  1. Union for International Cancer Control. What is TNM? [Internet]. [place unknown]: Union for International Cancer Control; [cited year month day]. Available from: https://www.uicc.org/resources/tnm.
  2. Brierley JD, Catton PA, O'Sullivan B, Dancey JE, Dowling AJ, Irish JC, et al. Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center. J Clin Oncol 2002;20:413-419. https://doi.org/10.1200/JCO.2002.20.2.413
  3. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. Basel: Springer; 2017.
  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. https://doi.org/10.1002/ijc.29210
  5. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-209. https://doi.org/10.1038/nature13480
  6. Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med 2015;21:449-456. https://doi.org/10.1038/nm.3850
  7. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141:476-485, 485.e1-485.e11. https://doi.org/10.1053/j.gastro.2011.04.042
  8. Choi YY, Cheong JH. Beyond precision surgery: molecularly motivated precision care for gastric cancer. Eur J Surg Oncol 2017;43:856-864. https://doi.org/10.1016/j.ejso.2017.02.013
  9. Cheong JH, Yang HK, Kim H, Kim WH, Kim YW, Kook MC, et al. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncol 2018;19:629-638. https://doi.org/10.1016/S1470-2045(18)30108-6
  10. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al.CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  11. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Stat Med 1984;3:143-152. https://doi.org/10.1002/sim.4780030207
  12. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. https://doi.org/10.1245/s10434-010-0985-4
  13. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol 2017;3:1197-1203. https://doi.org/10.1001/jamaoncol.2016.6762
  14. Choi YY, Kim H, Yang HK, Kim WH, Kim YW, Kook MC, et al. Clinical impact of microsatellite instability in patients with stage II and III gastric cancer: results from the CLASSIC trial. J Clin Oncol 2017. doi:10.1200/JCO.2017.35.15_suppl.4022.
  15. Nakajima T, Nashimoto A, Kitamura M, Kito T, Iwanaga T, Okabayashi K, et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Lancet 1999;354:273-277. https://doi.org/10.1016/S0140-6736(99)01048-X
  16. Han DS, Suh YS, Kong SH, Lee HJ, Choi Y, Aikou S, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol 2012;30:3834-3840. https://doi.org/10.1200/JCO.2012.41.8343
  17. Choi YY, An JY, Katai H, Seto Y, Fukagawa T, Okumura Y, et al. A lymph node staging system for gastric cancer: a hybrid type based on topographic and numeric systems. PLoS One 2016;11:e0149555. https://doi.org/10.1371/journal.pone.0149555

Cited by

  1. Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon vol.60, pp.3, 2019, https://doi.org/10.3349/ymj.2019.60.3.235
  2. Anatomical location-based nodal staging system is superior to the 7 th edition of the American Joint Committee on Cancer staging system among patients with surgically resected, histologica vol.14, pp.2, 2018, https://doi.org/10.1371/journal.pone.0211836
  3. Clinical Implementation of Precision Medicine in Gastric Cancer vol.19, pp.3, 2018, https://doi.org/10.5230/jgc.2019.19.e25
  4. Clinical Implications of Microsatellite Instability in Early Gastric Cancer vol.19, pp.4, 2018, https://doi.org/10.5230/jgc.2019.19.e38
  5. Emerging precision therapies for gastric cancer vol.5, pp.4, 2018, https://doi.org/10.1080/23808993.2020.1760089
  6. Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma vol.22, pp.11, 2018, https://doi.org/10.1080/14656566.2021.1900823